Mar 25, 2021 04:30 PM (GMT+8) · EqualOcean
Shanghai newpulse Medical Technology Co., Ltd. announced the completion of more than US $100 million round C financing. In this round of financing, Temasek led investment, Yunfeng, chengpang fund and old shareholders OrbiMed, Dachen Caizhi, Boyuan capital, Zhangke Lingyi, Junzi investment and other follow-up investments. Haoyue capital acted as the exclusive Financial Consultant of this round of financing. This round of financing will be used for the company to accelerate the research and development of interventional products for structural heart disease, and promote the clinical trials and registration of mitral valve replacement, repair products and balloon dilated aortic valve replacement products.